Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, U.S.A.
Department of Medicine (Division of Hematology, Oncology, and Transplantation), University of Minnesota, Minneapolis, MN 55455, U.S.A.
Essays Biochem. 2021 Dec 17;65(6):971-983. doi: 10.1042/EBC20200165.
The classification and treatment of breast cancer is largely defined by the expression of steroid hormone receptors (HRs), namely estrogen receptor (ER) and progesterone receptor (PR), and gene amplification/overexpression of human epidermal growth factor receptor 2 (HER2). More recently, studies of androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR) have revealed that targeting these related HRs may be a promising strategy for a more personalized approach to the treatment of specific subtypes of HR+ breast cancer. For example, GR expression is associated with a good prognosis in ER+ breast cancer, but predicts poor prognosis in triple-negative breast cancer (TNBC). GR, like ER, PRs, and AR, is a ligand-activated transcription factor, but also has significant ligand-independent signaling activities. GR transcriptional activity is classically regulated by circulating glucocorticoids (GCs; ligand-dependent). Recent studies demonstrate that GR transcriptional activity is also regulated by a variety of cellular stress stimuli that input to GR Ser134 phosphorylation via rapid activation of the p38 mitogen activated protein kinase (MAPK) signaling pathway (ligand-independent). Furthermore, ligand-independent GR activation promotes feedforward signaling loops that mediate sustained activation of stress signaling pathways to drive advanced cancer biology (i.e. migration, invasion, chemoresistance, survival, and cellular growth). In this review, we will focus on the role of GR as a key sensor and mediator of physiologic and tumor microenvironment (TME)-derived cellular stress signaling in TNBC and discuss how targeting GR and/or associated signaling pathways may provide a strategy to inhibit deadly TNBC progression.
乳腺癌的分类和治疗在很大程度上取决于甾体激素受体(HRs)的表达,即雌激素受体(ER)和孕激素受体(PR),以及人表皮生长因子受体 2(HER2)的基因扩增/过表达。最近,对雄激素受体(AR)、糖皮质激素受体(GR)和盐皮质激素受体(MR)的研究表明,靶向这些相关 HR 可能是针对特定 HR+乳腺癌亚型的更个性化治疗方法的一种有前途的策略。例如,GR 表达与 ER+乳腺癌的良好预后相关,但预测三阴性乳腺癌(TNBC)的预后不良。GR 与 ER、PRs 和 AR 一样,是一种配体激活的转录因子,但也具有显著的配体非依赖性信号转导活性。GR 转录活性经典地受循环糖皮质激素(GC;配体依赖性)调节。最近的研究表明,GR 转录活性也受各种细胞应激刺激的调节,这些刺激通过快速激活 p38 丝裂原活化蛋白激酶(MAPK)信号通路(配体非依赖性)输入到 GR Ser134 磷酸化。此外,配体非依赖性 GR 激活促进正向信号环路,介导应激信号通路的持续激活,从而推动晚期癌症生物学(即迁移、侵袭、化疗耐药性、存活和细胞生长)。在这篇综述中,我们将重点讨论 GR 作为 TNBC 中生理和肿瘤微环境(TME)衍生细胞应激信号的关键传感器和介质的作用,并讨论靶向 GR 和/或相关信号通路如何为抑制致命性 TNBC 进展提供策略。